MedTrace Logo

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

NCT00751530 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 442

Last updated 2017-07-02

Study results available
· View outcomes & findings →

Summary

This is a retrospective chart review of participants in raltegravir expanded access program and will compare virologic response in regimens not containing a protease inhibitor in the antiretroviral background regimen to regimens containing a protease inhibitor in the background regimen.

Conditions

  • HIV Infections

Interventions

DRUG

raltegravir

New combination ART incorporating raltegravir with other ARVs.

Sponsors & Collaborators

  • Community Research Initiative of New England

    lead OTHER

Principal Investigators

  • Daniel Skiest, MD · Community Research Initiative

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-01
Primary Completion
2009-06-15
Completion
2009-06-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00751530 on ClinicalTrials.gov